A non-randomized, single-panel, open-label trial to study the safety, tolerability and pharmacodynamics of MK-8892 acute dosing in subjects with moderate to severe pulmonary arterial hypertension

Trial Profile

A non-randomized, single-panel, open-label trial to study the safety, tolerability and pharmacodynamics of MK-8892 acute dosing in subjects with moderate to severe pulmonary arterial hypertension

Discontinued
Phase of Trial: Phase I

Latest Information Update: 05 Dec 2014

At a glance

  • Drugs MK-8892 (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Pharmacodynamics
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 02 Dec 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 31 Jul 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Aug 2014 to 1 Sep 2014.
    • 01 Nov 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top